shown that p53 gene mutations may be less common in areas with a low prevalence of hepatocellular carcinoma such as Great Britain. The protein product of mutant p53 can be detected immunohistochemically because of its longer half life in comparison with native protein. This study used a novel monoclonal antibody DO-7, raised against recombinant p53 and effective in routinely processed biopsy specimen tissue, to detect the mutant protein in a series of 45 cases of hepatoceliular carcinoma occurring in white subjects resident in the United Kingdom. Focal nuclear labelling was seen in four cases (9%); surrounding cirrhotic tissue in one of these was negative for p53 expression. This study shows that p53 mutations are a rare event in hepatocarcinogenesis in Great Britain, an area of low aflatoxin exposure, and supports the concept of geographical variations in the cause and pathogenesis of hepatocellular carcinoma. (Gut 1994; 35: 98-100) exposure, and this contrasts with the less specific pattern of mutations reported in other tumours.
I I These mutations are G to T transversions and it is postulated that they are related to aflatoxin damage as this carcinogen is known to bind to guanine in DNA causing G to T mutations.'" This contrasts with the infrequent finding of p53 mutations in hepatocellular carcinoma from areas oflow prevalence; these mutations are neither confined to codon 249 nor to GT trans-
The biological significance of these various point mutations is, however, far from clear. Not all point mutations have the same functional effect on p53 and this includes the inability of some mutations to stabilise the protein. ' ground staining was higher, however, using CM-I compared with DO-7 (Fig 1B) . In the four positive hepatocellular carcinoma tissue blocks surrounding cirrhotic tissue was present in one and was negative for p53 (Fig 2) . In 10 p53 negative tumours surrounding cirrhotic tissue was also negative. The Table shows 
